The Cancer Research UK-funded Clinical Trials & Statistics Unit (ICR-CTSU) provides the scientific leadership and operational management to develop, conduct and report high quality, innovative randomised trials, with integrated translational and psychosocial research.
ICR-CTSU is a National Clinical Research Institute (NCRI) Accredited and UK Clinical Research Collaboration (UKCRC) Registered Clinical Trials Unit with an established track record.
Recently published trials have led directly to changes in clinical practice. Our research work is focussed in selected clinical and therapeutic areas, with Dr Hall leading the ICR-CTSU Urology and Head and Neck Trials Team.
The aims of the ICR-CTSU’s research are to continue to develop, conduct and report high quality trials, and associated research of scientific importance, that will impact directly on clinical practice within the NHS and internationally. Building on past successes, and recognising the changing national and international priorities for clinical trials, our programme of trials have the following focus:
• Improving the effectiveness of radiotherapy through tailoring of treatment, hypofractionation and developments in radiotherapeutic technique
• Development of targeted therapies in castrate refractory disease
Muscle invasive bladder cancer
• Developing tailored bladder preservation strategies through improvements in (chemo) radiotherapeutic technique
Non-muscle invasive bladder cancer
• Developing trials in the surgical setting
Rare urological cancers
• Developing trials in penile and upper urinary tract cancers
• Collaborating internationally to extend the pool of eligible patients
• Improving outcomes for patients undergoing systemic therapy
Head and neck cancers
• Improving the effectiveness of radiotherapy through hypofractionation and developments in radiotherapeutic technique
Fundamental to both the scientific hypothesis, and to the conduct of these trials, is the targeting of treatments towards patients with the most potential for therapeutic gain. In addition to evaluation of therapeutic outcome, scientific output will be maximised by integrated biomarker directed translational research; patient assessed quality of life and symptom evaluations and statistical and trial methodology research.